Kiniksa Pharmaceuticals International, plc $KNSA Shares Acquired by Janus Henderson Group PLC

Posted by Geri Gentry on Aug 4th, 2026

Janus Henderson Group PLC increased its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) by 213.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 481,023 shares of the company’s stock after purchasing an additional 327,595 shares during the quarter. Janus Henderson Group PLC’s holdings in Kiniksa Pharmaceuticals International were worth $23,197,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its position in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $31,000. KBC Group NV purchased a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $34,000. Smartleaf Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the transaction, the director owned 11,672 shares in the company, valued at $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 51.98% of the stock is owned by corporate insiders.

Analyst Ratings Changes

KNSA has been the subject of several research analyst reports. Citigroup raised their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 29th. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $87.38.

View Our Latest Analysis on Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $73.41 on Tuesday. The company has a market cap of $5.65 billion, a price-to-earnings ratio of 75.68 and a beta of 0.05. The stock’s 50-day moving average is $59.44 and its two-hundred day moving average is $51.44. Kiniksa Pharmaceuticals International, plc has a 1-year low of $31.78 and a 1-year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The business had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.38 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

(Free Report)

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.